17912-87-7
CAS 17912-87-7
17912-87-7 (CAS 17912-87-7) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24714.316279069768 nM | 38 | - |
| - | MIC | 45.457142857142856 ug.mL-1 | 14 | - |
| - | IC50 | 30774.282 nM | 9 | - |
| - | EC50 | 12017.333333333334 nM | 3 | - |
| - | AC50 | 9800 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 17912-87-7 used for in pharmaceutical contexts?
17912-87-7 (CAS 17912-87-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 17912-87-7?
No adverse-event association or SIDER side-effect rows are rendered for 17912-87-7 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 17912-87-7 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Myricitrin with EU status "permitted".
What clinical phase is 17912-87-7 in?
No phase 1-4 clinical development badge is rendered for 17912-87-7 because the matched compound identifier rows do not contain a max-phase value.